Lindberg Felicia, Gabri Alexander, Kristiansson Helena, Gubanski Michael, Höybye Charlotte, Olsson Martin, Förander Petter, Skyrman Simon, Lippitz Bodo, Fletcher-Sandersjöö Alexander, Bartek Jiri
Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden.
Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
Acta Neurochir (Wien). 2024 Dec 6;166(1):494. doi: 10.1007/s00701-024-06341-2.
Gamma Knife radiosurgery (GKRS) is a well-established treatment for residual or growing pituitary adenomas (PAs) post-partial resection. However, some PAs grow even after initial GKRS, for which the efficacy of repeat GKRS is unclear. The primary objective of this study was to determine long-term progression-free survival (PFS) following repeated GKRS in patients with PA. The secondary objective was to determine predictors of tumor progression in these patients.
Single-center, population-based consecutive cohort study of patients with recurrent PAs treated with repeated GKRS due to tumor progression between 1999 and 2022 at the Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden. PFS and predictors of tumor growth were assessed.
23 patients were included, with a median follow-up time of 6.3 years. The 5-year PFS rate was 57%, and the median duration from repeat GKRS to tumor progression was 2.6 years. Tumor growth after repeat GKRS occurred exclusively within the first three years post-treatment. Older age at the time of repeat GKRS was a significant predictor of continued tumor growth (OR 1.09, p = 0.036).
Repeat GKRS is a feasible treatment alternative for PAs that exhibit growth following initial GKRS.
伽玛刀放射外科治疗(GKRS)是垂体腺瘤(PA)部分切除术后残留或生长的既定治疗方法。然而,一些垂体腺瘤在初次GKRS后仍会生长,重复GKRS的疗效尚不清楚。本研究的主要目的是确定垂体腺瘤患者重复GKRS后的长期无进展生存期(PFS)。次要目的是确定这些患者肿瘤进展的预测因素。
对1999年至2022年期间在瑞典斯德哥尔摩卡罗林斯卡大学医院神经外科因肿瘤进展接受重复GKRS治疗的复发性垂体腺瘤患者进行单中心、基于人群的连续队列研究。评估无进展生存期和肿瘤生长的预测因素。
纳入23例患者,中位随访时间为6.3年。5年无进展生存率为57%,从重复GKRS到肿瘤进展的中位持续时间为2.6年。重复GKRS后肿瘤生长仅发生在治疗后的前三年内。重复GKRS时年龄较大是肿瘤持续生长的显著预测因素(OR 1.09,p = 0.036)。
对于初次GKRS后出现生长的垂体腺瘤,重复GKRS是一种可行的治疗选择。